• LAST PRICE
    18.5000
  • TODAY'S CHANGE (%)
    Trending Up1.0500 (6.0172%)
  • Bid / Lots
    18.0000/ 3
  • Ask / Lots
    18.7900/ 1
  • Open / Previous Close
    17.7300 / 17.4500
  • Day Range
    Low 17.5200
    High 19.2932
  • 52 Week Range
    Low 10.0040
    High 24.4000
  • Volume
    12,158
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 17.45
TimeVolumeCDTX
09:32 ET110718.32
09:35 ET60017.52
09:37 ET10818.8594
09:42 ET21018.3312
09:53 ET13418.367
10:02 ET30018.0957
10:04 ET39818.4583
10:06 ET42018.2229
10:09 ET13518.2358
10:11 ET40818.24
10:15 ET10018.25
10:18 ET179318.5
10:20 ET31018.48
10:22 ET19418.2
10:24 ET30018.25
10:26 ET50018.5
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCDTX
Cidara Therapeutics Inc
123.0M
-0.7x
---
United StatesIPHA
Innate Pharma SA
130.4M
-3.9x
---
United StatesADAP
Adaptimmune Therapeutics PLC
162.8M
-2.9x
---
United StatesBIOQ
Bioqual Inc
60.4M
126.2x
-25.28%
United StatesMDXH
MDxHealth SA
84.6M
-1.1x
---
United StatesRPTX
Repare Therapeutics Inc
126.3M
-1.5x
---
As of 2024-11-22

Company Information

Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.

Contact Information

Headquarters
6310 Nancy Ridge Dr Ste 101SAN DIEGO, CA, United States 92121-3209
Phone
858-752-6170
Fax
302-655-5049

Executives

Independent Chairman of the Board
Daniel Burgess
President, Chief Executive Officer, Director
Jeffrey Stein
Chief Financial Officer
Preetam Shah
Chief Operating Officer, Company Secretary
Shane Ward
Chief Scientific Officer
Leslie Tari

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$123.0M
Revenue (TTM)
$18.9M
Shares Outstanding
7.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.05
EPS
$-26.06
Book Value
$-1.81
P/E Ratio
-0.7x
Price/Sales (TTM)
6.5
Price/Cash Flow (TTM)
---
Operating Margin
-678.73%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.